» Authors » Zoltan Hernadi

Zoltan Hernadi

Explore the profile of Zoltan Hernadi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 28
Citations 135
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Szabo Z, Juhasz E, Schally A, Dezso B, Huga S, Hernadi Z, et al.
Molecules . 2022 May; 27(9). PMID: 35566020
Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of various tumors, including endometrial carcinomas (EC). However, tumoral receptors that mediate the antiproliferative effects of GHRH antagonists in human ECs...
2.
Krasznai Z, Bagoly Z, Nagy E, Farkas Z, Poka R, Torok P, et al.
Orv Hetil . 2021 May; 162(20):790-799. PMID: 33999853
Summary: Introduction: Despite the use of human papillomavirus (HPV) testing, the management of the transitional categories of cytology-based screening still remains a challenge. The modern multimodal hyperspectroscopy (MHS) of the...
3.
Toth L, Nagy B, Mehes G, Laszlo E, Molnar P, Poka R, et al.
Pathol Res Pract . 2018 May; 214(7):978-985. PMID: 29801775
Introduction: Peritoneal dissemination accompanied by ascites formation is common in epithelial ovarian cancer (EOC). Adhesion molecules are crucial in metastatic spread and the latter involves epithelial-mesenchymal transition (EMT). This study...
4.
Koiss R, Boncz I, Hernadi Z, Szentirmay Z
Orv Hetil . 2017 Dec; 158(52):2062-2067. PMID: 29285941
Two main considerations played roles in creation of new cervical screening system. One was the proven fact that high-risk human papilloma virus infection plays a role in the development of...
5.
Nagy B, Toth L, Molnar P, Mehes G, Thurzo L, Poka R, et al.
Pathol Res Pract . 2017 Jun; 213(8):915-921. PMID: 28651933
Background: Classical features as histomorphology, grade, FIGO stage, and residual tumour mass have strong prognostic value in advanced epithelial ovarian carcinomas (AEOC). Most AEOCs are associated with early recurrence and...
6.
Poka R, Molnar S, Darago P, Lukacs J, Lampe R, Krasznai Z, et al.
Int J Gynecol Cancer . 2017 Jun; 27(7):1438-1445. PMID: 28604460
Objective: The aim of our study was to evaluate clinical and pathological data in order to draw eligibility criteria for oncologically sufficient radical trachelectomy (RT) in early-stage cervical cancer. Reviewing...
7.
Kasler M, Acs N, Bata Z, Danko D, Hernadi Z, Kalman M, et al.
Orv Hetil . 2015 Dec; 153 Suppl 4:1-39. PMID: 26686555
No abstract available.
8.
Acs N, Bata Z, Danko D, Hernadi Z, Kalman M, Kornya L, et al.
Orv Hetil . 2013 May; 153 Suppl:3-38. PMID: 23687666
No abstract available.
9.
Kim K, Hernlund E, Hernadi Z, Revesz J, Pete I, Szantho A, et al.
Int J Gynecol Cancer . 2013 May; 23(5):823-32. PMID: 23666016
Objective: Despite the considerable disease burden of ovarian cancer, there were no cost studies in Central and Eastern Europe. This study aimed to describe treatment patterns, health care utilization, and...
10.
Ferenczi A, Gyongyosi E, Szalmas A, Hernadi Z, Toth Z, Konya J, et al.
J Med Virol . 2013 Mar; 85(5):852-9. PMID: 23508911
About one-third of human papillomavirus (HPV) types infect the anogenital tract. High-risk genital HPV types (such as HPV 16, 18, 31, 33, and 35) are linked causally to the development...